A Phase 2 interventional study of 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice and 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice in Dentine Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-05-29.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.
Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 6 in phase 2, and was the 5th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.
Browse Dentin Sensitivity studies →None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →
Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2012.
This study's enrollment of 140 is above the median of 60 across 281 interventional studies indexed under Dentin Sensitivity.
Median enrollment 164 across the 28 interventional studies. Of the 27 that completed or were terminated, 27 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.
This will be a single center, eight week, randomized, controlled, examiner blind, four treatment arm, parallel design, stratified (by maximum baseline Schiff Sensitivity Score of the two selected test teeth), exploratory study in participants with at least two sensitive teeth that meet all the criteria at the Screening and Baseline visit. Participants will be assessed at Baseline, four and eight weeks to monitor clinical efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Drug: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice
Dentifrice containing 1000 ppmF as sodium monofluorophosphate
Drug: Sodium monofluorophosphate dentifrice
Dentifrice containing 1100 ppmF as sodium fluoride
Drug: Sodium fluoride dentifrice
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Dentifrice containing 1000 ppmF as sodium monofluorophosphate
Dentifrice containing 1100 ppmF as sodium fluoride
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
Time frame: Baseline to 4 weeks post administration of study treatment
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
Time frame: Baseline to 4 weeks post administration of study treatment
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
Time frame: Baseline to 8 weeks post administration of study treatment
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
Time frame: Baseline to 8 weeks post administration of study treatment
Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).
Time frame: Baseline to 4 weeks post administration of study treatment
Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).
Time frame: Baseline to 8 weeks post administration of study treatment
Participants were recruited at the clinical site.
| Milestone | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride |
|---|---|---|---|---|
| Started | 34 | 33 | 34 | 33 |
| Completed | 34 | 33 | 34 | 33 |
| Not completed | 0 | 0 | 0 | 0 |
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
| Score on a scale | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4 | -0.36 (-0.53 to -0.20) | -0.43 (-0.59 to -0.27) | -0.40 (-0.57 to -0.23) | -0.45 (-0.62 to -0.28) |
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
| grams | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4 | 7.31 ± 11.227 | 6.32 ± 13.045 | 4.09 ± 4.752 | 3.64 ± 6.030 |
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
| Score on a scale | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8 | -0.55 (-0.78 to -0.33) | -0.43 (-0.66 to -0.20) | -0.43 (-0.66 to -0.20) | -0.92 (-1.15 to -0.68) |
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
| grams | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8 | 10.15 ± 15.100 | 5.88 ± 11.512 | 4.39 ± 5.556 | 11.97 ± 16.486 |
Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).
| Score on a scale | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4 | -1.22 (-1.76 to -0.69) | -1.07 (-1.60 to -0.55) | -1.35 (-1.89 to -0.81) | -1.25 (-1.80 to -0.71) |
Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).
| Score on a scale | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate |
|---|---|---|---|---|
| Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8 | -1.76 (-2.35 to -1.17) | -1.22 (-1.81 to -0.63) | -1.31 (-1.90 to -0.71) | -2.06 (-2.67 to -1.46) |
Collected over Adverse events were collected collected from the start of the investigational product (or washout product), and until 5 days following last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | — | 0/34 (0%) | 0/34 (0%) |
| 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | — | 0/33 (0%) | 0/33 (0%) |
| Sodium Monofluorophosphate | — | 0/34 (0%) | 0/34 (0%) |
| Sodium Fluoride | — | 0/33 (0%) | 0/33 (0%) |
| Age, Continuous(Years) | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | Total |
|---|---|---|---|---|---|
| Mean | 35.4 ± 10.45 | 33.2 ± 10.13 | 38.2 ± 8.88 | 36.2 ± 9.62 | 35.8 ± 9.85 |
| Sex: Female, Male(Participants) | 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate | Sodium Monofluorophosphate | Sodium Fluoride | Total |
|---|---|---|---|---|---|
| Female | 25 | 24 | 27 | 22 | 98 |
| Male | 9 | 9 | 7 | 11 | 36 |
The record gives a start of Aug 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.